Open AccessCOVID-19 Induced Immunosuppression resulting in Pulmonary Mucormycosis : A Long COVID sequalae
Author(s) -
Dhruv Talwar,
Sunil Kumar,
Sourya Acharya,
Sparsh Madaan,
Vidyashree Hulkoti
Publication year - 2021
Publication title -
journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.121
H-Index - 5
eISSN - 2075-5384
pISSN - 1997-9797
DOI - 10.3329/jom.v22i2.56707
Subject(s) - medicine , mucormycosis , immunosuppression , posaconazole , covid-19 , bronchoalveolar lavage , zygomycosis , incidence (geometry) , ards , respiratory distress , lung , amphotericin b , dermatology , surgery , antifungal , disease , infectious disease (medical specialty) , physics , optics
With increasing incidence of Severe Acute Respiratory Distress Virus 2(SARS -CoV -2) in India, there has been growing reports of super infections in post covid 19 period. Long COVID refers to persistence of COVID19 symptoms for weeks to months. While most common manifestation of long COVID is fatigue and ill health, it may lead to development of life-threatening complications like Pulmonary Mucormycosis. We report a case of 54 year young, non-diabetic previously healthy male who had moderate COVID19 treated with low dose steroids and recovered completely, only to present with hemoptysis 3 months later on High Resolution Computed Tomography Scan of the Chest and Rhizopus fungi on bronchoalveolar lavage confirming Post Covid Pulmonary Mucormycosis in non-immunocompromised host. Patient was managed with dual antifungal therapy intravenous Liposomal Amphotericin B and Posaconazole for 3 weeks, followed by oral Posaconazole.J MEDICINE 2021; 22: 150-154